

MEDIA RELEASE

MAMMAPRINT EMPOWERS BREAST CANCER PATIENTS TO SAFELY FOREGO CHEMOTHERAPY

- In the MINDACT¹ Trial, up to 46% of breast cancer patients identified using MammaPrint as high risks of their cancer recurring and therefore candidates for chemotherapy, were found to have insignificant benefits from it
- MammaPrint helps to empower early stage breast cancer patients to safely forego chemotherapy and lower overall treatment costs

Singapore, 8 June 2018 – Angsana Molecular & Diagnostics Laboratory Pte Ltd, a Parkway Pantai subsidiary, offers MammaPrint to benefit breast cancer patients in Singapore and across Southeast Asia. In the MINDACT Trial, the use of MammaPrint was found to be able to spare up to 46% of early stage breast cancer patients from potentially painful chemotherapy.

“Cancer treatments can be associated with debilitating side effects; but because it has been the focus of adjuvant therapy to reduce the risk of recurrence in breast cancer; it has been routinely recommended,” says **Dr See Hui Ti, Medical Oncologist at Parkway Cancer Centre, Mount Elizabeth Hospital**. “MammaPrint provides clinically actionable information for patients and their oncologists to make informed, confident decisions about their treatments; where it comes to foregoing chemotherapy. The gains are considerable, in the quality of life and cost benefit of identifying women previously selected for chemotherapy that may not have significant benefit from it.”

MammaPrint analyses 70 genes most associated with the natural history of aggressive and non-aggressive breast cancer and provides a binary result to identify early-stage breast cancer patients who are at a genomic Low or High Risk for distant metastasis within five years. The clinical utility of the MammaPrint test has been demonstrated by the MINDACT trial. It showed, with the highest level of clinical evidence, that 46% of patients identified as high risk for recurrence according to clinical-pathological factors and who would otherwise be typical candidates for adjuvant chemotherapy were reclassified as Low Risk by MammaPrint, indicating insignificant benefit from chemotherapy.

“Over-treating patients could lead to increased healthcare costs for patients and is a strain on healthcare resources. Precision medicine and molecular diagnostics tests such as MammaPrint helps doctors make informed and personalized treatment plans based on the genomic subtype and characteristics of individual patients, reducing the risk of overtreatment,” says **Dr Daniel Tan, Chief Executive Officer of Parkway Laboratory and Chief Executive Officer of Angsana Molecular & Diagnostics Laboratory**.

Breast cancer accounted for almost 1 in 3 (29.1%) cancer diagnosis among Singapore women, making it the most common cancer among women. Close to 9000 Singaporean women were diagnosed with breast cancer between 2011 and 2015.

¹ About MINDACT

MINDACT is a prospective, randomized, phase III, controlled clinical trial that investigated the clinical utility of MammaPrint, when used in conjunction with standard clinical pathological criteria, for the selection of patients unlikely to benefit from adjuvant chemotherapy. From 2007 to 2011, 6,693 women who had undergone surgery for early-stage breast cancer were enrolled in the trial, across 112 centers in nine countries

For media queries, please contact:

Constance Lim
Group Corporate Communications
Parkway Pantai Limited
DID 6349 5743
HP 8121 8186
Email constance.lim@parkwaypantai.com

Matthew Loh
Group Corporate Communications
Parkway Pantai Limited
DID 6415 7815
HP 9170 2541
Email matthew.loh@parkwaypantai.com

About Parkway Pantai

Parkway Pantai is one of Asia's largest integrated private healthcare groups operating in Singapore, Malaysia, India, China, Brunei and United Arab Emirates. For over 40 years, its Mount Elizabeth, Gleneagles, Pantai and Parkway brands have established themselves as the region's best known brands in private healthcare, synonymous with best-in-class patient experience and outcomes.

Leveraging its global track record for medical excellence and managing world-class hospitals, Parkway Pantai is committed to making a difference in people's lives through excellent patient care, steadily expanding its reach in markets where demand for quality care is strong and growing.

Parkway Pantai is a leading healthcare player in its home markets of Singapore, Malaysia and India and key growth markets of China and Hong Kong.

It is part of IHH Healthcare, one of the world's largest healthcare groups by market capitalisation. IHH operates more than 10,000 licensed beds across 49 hospitals in 9 countries worldwide, offering the full spectrum of integrated healthcare services from clinics to hospitals to quaternary care and a wide range of ancillary services including medical education.

For more information, please visit www.parkwaypantai.com.

About Angsana Molecular & Diagnostics

Angsana Molecular & Diagnostics specialises in developing premium molecular diagnostic assays, serving the following four medical areas that have the largest impact in Asian population: allergy and molecular allergology, fetal maternal health, molecular oncology and pharmacogenetics.

Through analysis of medical conditions at a molecular level, combined with clinical consultation by board-certified medical geneticists and sub-specialty trained pathologists, Angsana empowers clinicians and patients to make better informed clinical decisions and improve the quality of patient care.

Strategically located in Asia with multi-laboratory operations in Singapore, Hong Kong and Malaysia, Angsana Molecular & Diagnostics is dedicated to serving the Asian community with fast and more affordable services within easy reach.

For more information, visit www.angsanadx.com.